Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ('Aclarion' or the 'Company') (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan product is now available in Santa Monica at Medical Imaging Center of Southern California (MICSC). Until now, MICSC has provided Nociscan exclusively at their Beverly Hills location.
'We are pleased to expand access to Nociscan in our Santa Monica location,' said Bradley Jabour, MD, founder of MICSC. 'MICSC has a proud heritage of adoption of new and novel solutions that add value to our patients and referring physician customers. Nociscan has been an integral part of our Beverly Hills service offering and by adding it in Santa Monica we are expanding our services while replicating the benefits to patients and physicians currently provided in Beverly Hills. Physicians treating low back pain are constantly striving for more and better information when diagnosing and treating patients. Nociscan is helping physicians who treat low back pain and we are pleased to offer Nociscan at both our Los Angeles locations.'
In November 2024, Dr. Jabour was highlighted in an article about Nociscan in the Radiological Society of North America edition of MAGNETOM Flash, a peer-to-peer magazine published by Siemens Healthineers. The article features two physician-user perspectives on Nociscan, one from a spine surgeon and the other from Dr. Jabour's point of view as a radiologist and imaging center owner.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Los Angeles is the most populous city in California, with an estimated population exceeding 3.8M people, and the second-most populous city in the United States, second only to New York City. Both Los Angeles and New York City are strategically important markets for Aclarion.
Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain.
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ('MRS'), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. SmithPCG Advisory, Inc.ksmith@pcgadvisory.com
Media Contacts:
Jennie KimSPRIG Consultingjennie@sprigconsulting.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
IgA Nephropathy Market Analysis Report 2025-2035: Innovation in Renal Therapies and Accelerated Drug Approvals Drive Growth
The global IgA nephropathy market is in growth due to rising awareness, better diagnostics, and advanced treatments like complement inhibitors. North America leads the market, supported by regulatory advantages. Key players such as Novartis are driving innovation, though high costs and competition remain challenges. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to global IgA nephropathy market is currently in the growth stage of its lifecycle, driven by increasing awareness, improved diagnostic capabilities, and advancements in renal treatment options. The market is expanding as novel therapies, such as complement inhibitors and non-immunosuppressive drugs, are gaining traction, addressing the unmet need for more effective renal treatments. With ongoing research and development, pharmaceutical companies are investing heavily in clinical trials to bring new, targeted therapies to market. The global IgA nephropathy market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare regulatory bodies are accelerating the approval process for innovative renal drugs, further fueling market growth. Despite this positive momentum, challenges such as high treatment costs and the variability in disease progression may hinder rapid expansion. As a result, the market is expected to continue growing, although competition and price pressures will likely intensify as more treatments emerge. North America is expected to dominate the global IgA nephropathy market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global IgA nephropathy market. How Can This Report Add Value to an Organization?Product/Innovation Strategy: Product launches and innovations in the global IgA nephropathy market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Novartis, and Travere Therapeutics, Inc., have been involved in the development of therapies for IgA Strategy: Enterprises led by market leaders in the global IgA nephropathy market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the Developments Regulatory Activities: In April 2025, the U.S. FDA granted accelerated approval for Novartis' Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy. Partnerships: In March 2025, Folia Health and Novartis Pharmaceuticals, Inc. announced their collaboration on an innovative at-home observational real-world evidence initiative aimed at supporting individuals with IgA nephropathy. Regulatory Activities: In November 2024, South Korea approved Everest Medicines' NEFECON for the treatment of primary IgA nephropathy. Regulatory Activities: In September 2024, Ligand partner Travere Therapeutics received FDA approval for FILSPARI (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy. Market Dynamics Drivers: Increasing Prevalence of IgA Nephropathy Continuous Advancements in Treatment Options Improved Diagnosis and Awareness Challenges: High Treatment Costs Limited Awareness in Developing Markets Key Market Players and Competition Synopsis Novartis F. Hoffmann-La Roche Ionis Pharmaceuticals Vertex Pharmaceuticals Otsuka Pharmaceutical Biogen Arrowhead Pharmaceuticals NovelMed Q32 Bio Walden Biosciences Takeda Pharmaceutical Vera Therapeutics Biocity Biopharmaceutics Co., Ltd. Calliditas Therapeutics AB Travere Therapeutics, Inc. Alexion Pharmaceuticals, Inc. Key Topics Covered: Executive SummaryScope and Definition1. Global IgA Nephropathy Market: Market Outlook1.1 Industry Outlook1.1.1 Market Overview and Ecosystem1.1.2 Market Trends1.1.3 Epidemiological Analysis of IgA Nephropathy1.1.3.1 By Region1.1.3.1.1 U.S.1.1.3.1.2 EU51.1.3.1.3 Rest-of-the-World1.1.4 Clinical Trials1.1.4.1 By Phase1.1.4.2 By Sponsor Type1.1.5 Regulatory Landscape / Compliance1.1.5.1 Legal Requirement and Framework in the U.S.1.1.5.2 Legal Requirement and Framework in the E.U.1.1.5.3 Legal Requirement and Framework in Asia-Pacific1.1.5.4 Legal Requirement and Framework in Rest-of-the-World1.2 Market Dynamics1.2.1 Impact Analysis1.2.2 Market Drivers1.2.3 Market Restraints1.2.4 Market Opportunities2. Global IgA Nephropathy Market (By Region), $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America IgA Nephropathy Market (by Country)2.1.3.1.1 U.S.2.1.3.1.2 Canada2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe IgA Nephropathy Market (by Country)2.2.3.1.1 U.K.2.2.3.1.2 Germany2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.2.3.1.6 Rest-of-Europe2.3 Asia-Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia-Pacific IgA Nephropathy Market (by Country)2.3.3.1.1 Japan2.3.3.1.2 China2.3.3.1.3 Rest-of-Asia-Pacific2.4 Rest-of-the-World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global IgA Nephropathy Market - Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Company Overview3.2.2 Product Portfolio3.2.3 Target Customers/End Users3.2.4 Analyst View4. Research MethodologyFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Human Gene Sequencing Markets, Strategies, Trends and Forecasts Report 2025: New Diagnoses, Wellness and Prevention, Fertility Technology, Cancer Screening, Management and Monitoring Fueling Growth
Explore the explosive growth of genome sequencing as costs plummet and demand rises. Our report reveals market forecasts, technology insights, and growth opportunities globally and across 14 countries. Uncover opportunities, understand industry jargon, and anticipate five-year growth expectations. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Human Gene Sequencing Markets, Strategies & Trends: Forecasts By Application, By Technology, By Workflow, By Product, and By Country with Executive and Consultant Guides" report has been added to offering. Will all newborns receive genetic testing at birth? What segments are growing fastest? Where are the opportunities now that sequencing has gone mainstream? The plummeting costs for Genome Sequencing are creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well-funded players are racing for market share on a global stage. This report forecasts the market size for five years. The report includes detailed breakouts for 14 countries and 5 regions. Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. Key Topics Covered: 1 Market Guides1.1 Human Gene Sequencing Markets - Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales, and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition2.1 Gene Sequencing Definition In This Report2.1.1 Gene Sequencing2.1.2 Hereditary2.1.3 Non-Invasive Prenatal Testing2.1.4 Oncology2.1.5 Psychology2.1.6 WGES2.1.7 Pharmacogenomic2.1.8 Direct-to-Consumer2.1.9 Research2.1.10 Other2.2 The Genomics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry2.5.1 Global Healthcare Spending2.5.2 Spending on Diagnostics2.5.3 Important Role of Insurance for Diagnostics2.6 Chromosomes, Genes and Epigenetics 3 Global Listing of Sequencer Installed Base - Location & Contacts3.1 Notes to Installed Base Listing3.2 Illumina Installed Base 4 Market Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 Human Gene Sequencing -Markets, Examples and Discussion4.2.1 Inherited Disease - Not what it used to be4.2.2 Newborn Screening - The Standard of Care4.2.3 NIPT - We've Only Just Begun4.2.4 Oncology - Understanding Two Worlds4.2.5 Pharmacogenomics4.2.6 Direct To Consumer - More Than Meets the Eye4.3 Industry Structure4.3.1 Hospital's Testing Share4.3.2 The Rise of the Sequencing Lab4.3.3 Sequencing as a Commodity4.3.4 Informatics4.3.5 Instrument Manufacturer Role4.3.6 Healthcare Industry Impacts - Still Struggling4.3.7 Can the Healthcare Industry Adapt?4.3.8 Genetic Counselling as an Industry4.3.9 Sequencing Adoption and Cannibalization 5 Market Trends5.1 Factors Driving Growth5.1.1 New Diagnoses5.1.2 Wellness and Prevention5.1.3 Fertility Technology5.1.4 Cancer - Screening, Management and Monitoring5.2 Factors Limiting Growth5.2.1 Increased Competition Lowers Price5.2.2 Lower Costs5.2.3 Healthcare Cost Concerns Curtail Growth5.2.4 Wellness has a downside5.3 Sequencing Instrumentation5.3.1 Instrumentation Tenacity5.3.2 Declining Cost of Instruments Changes Industry Structure5.3.3 Long Reads - Further Segmentation5.3.4 Linked Reads5.3.5 New Sequencing Technologies 6 Human Gene Sequencing Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 WGS Improves Pediatric Cancer Care6.3 Cancer genomes identify candidate driver genes6.4 Genetic Dx a game changer6.5 Nonacus Galeas Tumor6.6 Lucence LiquidHallmark Assay Gets Coverage6.7 Garvan Institute Gets Gramt to Develop Genomics Tests6.8 Arima Genomics, Protean BioDiagnostics Launch Joint Venture6.9 Geneseeq Nabs CE Marks for Cancer Test Kits6.10 Viome Life Sciences Announces Gut Intelligence Test6.11 Quest Diagnostics Announces Genetic Insights6.12 Exact Sciences Releases Next-Gen Cologuard6.13 BGI Genomics Forges Partnerships in Latin America6.14 4bases Bets on NGS Diagnostics6.15 Guardant Health Submits Colorectal Cancer Screening Test6.16 Universal DX Eyeing Approval for Colorectal Cancer Screening Test6.17 Natera Files Suit Against NeoGenomics6.18 Genomics England to Sequence 100K Newborns6.19 Novigenix Raises $14M for NGS based Liquid Biopsy6.20 LetsGetChecked Launching New PGx Service6.21 Qiagen, Neuron23 Partner for NGS Diagnostic6.22 Harbinger Health Technology Focused On Oncogenesis6.23 Delfi Diagnostics to Develop Early Detection Test6.24 Dante Labs to Introduce WGS to Italian Healthcare System6.25 Invitae Neurodevelopmental Disorders Testing Service6.26 Thermo Fisher Obtains CE Mark for Ion Torrent Genexus6.27 Myriad Genetics Launches Suite of Cancer Tests6.28 Oncocyte and Thermo Fisher Strike Partnership Deal6.29 Illumina Partners With Precision Medicine to Assess Liquid Biopsy 7 Profiles of Key Companies7.1 10x Genomics, Inc.7.2 23andME Inc.7.3 Abbott Laboratories7.4 AccuraGen Inc.7.5 Adaptive Biotechnologies7.6 Admera Health, LLC7.7 Advanced Biological Laboratories7.8 Agilent7.9 Akonni Biosystems7.10 Amoy Diagnostics Co., Ltd.7.11 LLC7.12 Anchor Dx7.13 Arrayit Corporation7.14 ARUP Laboratories7.15 Astrid Bio7.16 Azenta7.17 BaseClear7.18 Baylor Miraca Genetics Laboratories7.19 Beckman Coulter Diagnostics (Danaher)7.20 Becton, Dickinson and Company7.21 BGI Genomics Co. Ltd7.22 Bioarray Genetics7.23 BioBam7.24 Biocept, Inc.7.25 Biodesix Inc.7.26 BioFluidica7.27 BioGenex7.28 Biolidics Ltd7.29 bioMerieux Diagnostics7.30 Bioneer Corporation7.31 Bio-Rad Laboratories, Inc.7.32 Bio-Techne7.33 Burning Rock7.34 C2i Genomics7.35 Cantata Bio7.36 CareDx7.37 Caris Molecular Diagnostics7.38 Celemics7.39 CellMax Life7.40 Centogene7.41 Cepheid (Danaher)7.42 Circulogene7.43 Clearbridge Biomedics7.44 Clinical Genomics7.45 Color Genomics7.46 Complete Genomics (MGI Tech)7.47 CosmosID7.48 Dante Labs7.49 Datar Cancer Genetics Limited7.50 Diasorin S.p.A.7.51 Easy DNA7.52 Element Biosciences7.53 Epic Sciences7.54 Epigenomics AG7.55 Eurofins Scientific7.56 Excellerate Bioscience7.57 Fabric Genomics7.58 Freenome7.59 FUJIFILM Wako Diagnostics7.60 Fujirebio7.61 Fulgent Genetics7.62 GE Global Research7.63 Gene by Gene, Ltd.7.64 Genedrive7.65 GeneDx Holdings7.66 GeneFirst Ltd.7.67 GeneFluidics7.68 Genetron Holdings7.69 Genewiz7.70 Genomics England7.71 Genomics Personalized Health (GPH)7.72 GenomOncology7.73 Genzyme Corporation7.74 Grifols7.75 Guardant Health7.76 Guardiome7.77 Helix7.78 Hologic7.79 HTG Molecular Diagnostics7.80 Human Longevity, Inc.7.81 iCellate7.82 Illumina7.83 Incell Dx7.84 Inivata7.85 Invitae Corporation7.86 Invivoscribe7.87 Karius7.88 Letsgetchecked7.89 Lucence Health7.90 Lunglife AI Inc7.91 Macrogen7.92 MDNA Life SCIENCES, Inc.7.93 MDx Health7.94 Medgenome7.95 Meridian Bioscience7.96 Mesa Laboratories, Inc.7.97 Metabiomics Corp7.98 miR Scientific7.99 NantHealth, Inc.7.100 Natera7.101 Nebula Genomics7.102 NeoGenomics7.103 New England Biolabs, Inc.7.104 NGeneBio7.105 Norgen Biotek Corp.7.106 Novogene7.107 Omega Bioservices7.108 Oncocyte7.109 OncoDNA7.110 OpGen7.111 Origene Technologies7.112 Oxford Nanopore Technologies7.113 Pacific Biosciences7.114 Panagene7.115 PathoQuest S.A.7.116 Personalis7.117 PGDx (Labcorp)7.118 Precipio7.119 PrecisionMed7.120 Predictive Oncology7.121 Promega7.122 Qiagen7.123 QuantuMDx7.124 Regeneron Pharmaceuticals7.125 Revvity7.126 Roche Diagnostics7.127 Roswell Biotechnologies7.128 Seegene7.129 SeLux Diagnostics7.130 Siemens Healthineers7.132 simfo GmbH7.133 Singlera Genomics Inc.7.134 Singular Genomics7.135 SkylineDx7.136 Standard BioTools7.137 Sysmex7.138 Sysmex Inostics7.139 Tempus Labs, Inc.7.140 Thermo Fisher Scientific7.141 Ultima Genomics7.142 Unchained Labs7.143 Variantyx7.144 Vela Diagnostics7.145 VolitionRX7.146 Zymo Research Corp 8 The Global Market for Human Genome Sequencing8.1 Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Technology - Overview8.4 Global Market by Workflow - Overview8.5 Global Market by Product - Overview 9 Market Sizes by Application9.1 Hereditary Gene Sequencing Market9.2 NIPT Gene Sequencing Market9.3 Oncology Market9.4 Psychology Market9.5 WGES Gene Sequencing Market9.6 Pharmacogenomics Market9.7 DTC Gene Sequencing Market9.8 Research Gene Sequencing Market 10 Market Sizes by Technology10.1 Sanger Sequencing Market10.2 NGS/2G Market10.3 3G/Long Market 11 Market Sizes by Workflow11.1 Sequencing Market11.2 Sample Prep Market11.3 Analysis Market 12 Market Sizes by Product12.1 Instruments Market12.2 Consumables Market12.3 Software & Services Market 13 Vision of the Future of Human Gene Sequencing 14 Appendices14.1 Growth of Approved IVD Test Menu14.2 Growth of Approved Average IVD Test Fee14.3 The Most Used IVD Assays14.4 The Highest Grossing Assays14.5 Laboratory Fees Schedule14.6 The Whole Genome Sequence of SARS-CoV-2 For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Fit Cafe Announces Official Website Update Featuring Natural Daily Supplement for Energy, Mood, and Metabolic Support
New U.S. Wellness Brand Launches Plant-Based Morning Supplement to Support Clean Energy, Mood, and Metabolism SHERIDAN, June 09, 2025 (GLOBE NEWSWIRE) -- Fit Cafe™, a wellness-focused brand from Aspen Brass LLC, has updated its official website to share new information about its daily drink powder supplement designed to support clean energy, balanced mood, and metabolic wellness in adults. Now available in the U.S., the plant-based superfood formula offers a simple way to promote daily vitality without added sugar, gluten, or dairy. According to the official website ( Fit Cafe™ is formulated to align with the body's natural energy and digestion cycles. The company highlights the supplement's focus on convenience, offering a quick-to-mix powder that fits easily into a morning routine—no complicated diets or coffee-shop lines required. 'Fit Cafe™ is about more than just feeling energized—it's about helping people create a positive, health-forward ritual they actually enjoy,' said a company spokesperson. 'Our goal is to simplify wellness through clean, functional ingredients that support how real people live every day.' Fit Cafe™ is manufactured in quality-controlled U.S. facilities that adhere to rigorous safety standards. Its blend of superfoods, adaptogens, and nutrients is intended to support natural energy, promote a positive mood, and aid healthy metabolism—making it an ideal choice for individuals seeking a modern wellness solution without stimulants or added sugars. As noted on the official website, first-time customers are backed by a satisfaction guarantee. Full product details, ingredient information, and direct ordering options are available exclusively at About Fit Cafe™ Fit Cafe™ is a U.S.-based wellness brand developed by Aspen Brass LLC, offering natural, easy-to-use superfood supplements that support healthy daily routines. Built on a foundation of transparency and simplicity, the brand helps adults feel energized, balanced, and supported—starting with their morning ritual. Product and Contact Information Brand: Fit Cafe™Company: Aspen Brass LLCWebsite: care@ 844-240-3279Mailing Address: 1309 Coffeen Ave, Ste 17470, Sheridan, WY 82801Return Address: 4711 34th St N Suite F, St. Petersburg, FL 33714 Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: care@ Phone: 844-240-3279 Return Address: 4711 34th St N Suite F, St. Petersburg, FL 33714
